Status:
COMPLETED
A Study on the Efficacy and Safety of Continuous Renal Replacement Therapy (CVVHDF) Using a Commercial Citrate-containing Replacement Fluid (Prismocitrate 18/0)
Lead Sponsor:
The University of Hong Kong
Conditions:
Renal Failure
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The investigators aim to examine the efficacy and safety of using a new citrate containing commercially available solutions (Prismocitrate 18/0) as the regional citrate anticoagulation in continuous r...
Detailed Description
Acute kidney injury is common in critically ill patients, and continuous renal replacement therapy is the preferable mode of treatment to remove the metabolic waste while avoiding the hemodynamic inst...
Eligibility Criteria
Inclusion
- The patient requires CRRT as treatment for renal failure, as decided by the attending physician
- The patient fulfils at least one of the following clinical criteria for initiating CRRT:
- According to the RIFLE criteria, (11) patients satisfying the "injury" criteria (increase creatinine by 2 fold or urine output\<0.5ml/kg/hr for 12hr) will be considered for CRRT
- Hyperkalemia (\[K+\] \> 6.5 mmol/L).
- Severe acidemia (pH \< 7.2).
- Urea \> 25 mmol/liter.
- Clinically significant organ oedema in the setting of ARF.
Exclusion
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01921816
Start Date
May 1 2012
Last Update
December 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Adult Intensive Care unit, Queen Mary Hospital
Hong Kong, Hong Kong, 852